Aktis Oncology (NASDAQ:AKTS) Price Target Raised to $33.00

Aktis Oncology (NASDAQ:AKTS) had its price target boosted by HC Wainwright from $30.00 to $33.00 in a research report issued on Tuesday,Benzinga reports. The firm presently has a “buy” rating on the technology company’s stock. HC Wainwright’s price target indicates a potential upside of 99.52% from the company’s current price.

A number of other research firms have also issued reports on AKTS. Wall Street Zen raised shares of Aktis Oncology to a “hold” rating in a report on Saturday, January 17th. Leerink Partners initiated coverage on shares of Aktis Oncology in a research report on Tuesday, February 3rd. They set an “outperform” rating and a $31.00 price target on the stock. JPMorgan Chase & Co. began coverage on shares of Aktis Oncology in a research note on Tuesday, February 3rd. They set an “overweight” rating and a $30.00 price objective for the company. Bank of America assumed coverage on shares of Aktis Oncology in a report on Tuesday, February 3rd. They issued a “buy” rating and a $34.00 price objective for the company. Finally, TD Cowen assumed coverage on shares of Aktis Oncology in a research note on Tuesday, February 3rd. They issued a “buy” rating on the stock. Five investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Aktis Oncology has a consensus rating of “Buy” and an average price target of $32.00.

Aktis Oncology Price Performance

NASDAQ AKTS opened at $16.54 on Tuesday. The company has a fifty day moving average price of $19.21. Aktis Oncology has a one year low of $14.72 and a one year high of $29.16.

Insiders Place Their Bets

In other news, major shareholder Ansbert Gadicke purchased 1,112,777 shares of the stock in a transaction dated Monday, January 12th. The shares were purchased at an average price of $18.00 per share, with a total value of $20,029,986.00. Following the transaction, the insider owned 10,260,064 shares in the company, valued at $184,681,152. The trade was a 12.17% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Vida Ventures Ii, Llc acquired 835,000 shares of the company’s stock in a transaction that occurred on Monday, January 12th. The stock was purchased at an average cost of $18.00 per share, with a total value of $15,030,000.00. Following the acquisition, the insider directly owned 5,671,825 shares of the company’s stock, valued at $102,092,850. This trade represents a 17.26% increase in their position. The SEC filing for this purchase provides additional information. Over the last ninety days, insiders acquired 6,117,776 shares of company stock worth $110,119,968.

About Aktis Oncology

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.